ARWR: Moving Plozasiran Forward in Phase 3 CVOT… [Yahoo! Finance]
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Yahoo! Finance
On June 25, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) held a webinar (slides are available here ) on the company's cardiometabolic programs that included plans to move plozasiran forward into a cardiovascular outcomes trial (CVOT) and pause the development of zodasiran (will only move it forward into a Phase 3 trial with a partner). The details of the Phase 3 CAPITAN CVOT study are provided below. It will evaluate 25 mg plozasiran versus placebo in two cohorts: a secondary prevention cohort with triglyceride (TG) levels 200-800 mg/dl and non-HDL-cholesterol 100 mg/dl and a primary prevention cohort with TG levels 250-800 mg/dl and non-HDL-cholesterol 130 mg/dl. The primary endpoint is the time from randomization to the first occurrence of any of the endpoints of the 5-point MACE (Major Adverse Coronary Event) consisting of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, or major adverse limb events. The company wi
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.MarketBeat
- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- The past three years for Arrowhead Pharmaceuticals (NASDAQ:ARWR) investors has not been profitable [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.MarketBeat
- Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial [Yahoo! Finance]Yahoo! Finance
ARWR
Earnings
- 5/9/24 - Miss
ARWR
Sec Filings
- 7/3/24 - Form 4
- 7/2/24 - Form 144
- 5/9/24 - Form 10-Q
- ARWR's page on the SEC website